Vertex Pharmaceuticals Incorporated announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego. The new site represents a significant expansion of the Company’s research presence in the area, and its continued investment in the local economy. The San Diego site is one of Vertex’s three global research hubs, and is where the Company’s three breakthrough cystic fibrosis (CF) medicines were discovered.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“Our researchers in San Diego have spent the last 20 years doing what was once thought impossible – developing the first medicines that treat the underlying cause of cystic fibrosis,” said Dr. David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer. “This team is a critical part of our global research effort, and the new site will allow us to continue investing in science to bring more transformative medicines to people with serious diseases.”
More than 70 percent of the new facility is dedicated to state-of-the-art lab and research space. It features a 1,500 square foot learning lab for science, technology, engineering, arts and math (STEAM) education programs, expanding on the Company’s commitment to inspire and equip the next generation of leaders in science; and a 4,000 square foot incubator suite for external collaboration.
The new building, located at 3215 Merryfield Row, is LEED Gold certified and is surrounded by two acres of dedicated outdoor space. Construction of the new building was completed on schedule, in less than 18 months, and was overseen by Alexandria Real Estate. Vertex has committed to a 16-year lease to fully occupy the site.